VHIO genomic study identifies subgroups of HER2+ breast cancer with varying sensitivities

(Vall d´Hebron Institute of Oncology) VHIO describes as many as four subgroups of HER2+ breast cancer (Luminal A, Luminal B, HER2-enriched and Basal-Like) with varying responses and benefits resulting from combined anti-HER2 targeted therapy and chemotherapyThe first diagnostic test for these different breast cancer subtypes will soon be available at VHIO which will be key to ongoing studies.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news